Preliminary results of a phase I trial inspire the phase II KarMMa study of bb2121, an anti-B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T Cell therapy, for relapsed and refractory Multiple Myeloma (rrMM)

被引：0
|
作者：
Einsele, H. [1 ]
Goldschmidt, H. [2 ]
Weisel, K. [3 ]
Hege, K. [4 ]
Munshi, N. [5 ]
San Miguel, J. [6 ]
机构：
[1] Univ Clin Wuerzburg, Wurzburg, Germany
[2] Univ Clin Heidelberg, Heidelberg, Germany
[3] Univ Clin Tuebingen, Tubingen, Germany
[4] Celgene Corp, San Francisco, CA USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Clin Univ Navarra, Pamplona, Spain
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V409
引用
收藏
页码：134 / 134
页数：1
相关论文
共 50 条
  • [41] B- Cell Maturation Antigen (BCMA) Re-Emergence and Relapse Patterns Post-BCMA-Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Multiple Myeloma
    Wesson, William
    Cui, Wei
    Mushtaq, Muhammad
    Bansal, Rajat
    Singh, Anurag K.
    Hoffmann, Marc
    Tun, Aung M.
    Balusu, Ramesh
    Abdelhakim, Haitham
    Abhyankar, Sunil H.
    McGuirk, Joseph P.
    Shune, Leyla O.
    Abdallah, Al-Ola
    Ahmed, Nausheen
    BLOOD, 2022, 140 : 12781 - 12783
  • [42] Secondary Quality-of-Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel; bb2121): Results from the Karmma Clinical Trial
    Shah, Nina
    Delforge, Michel
    San-Miguel, Jesus F.
    Bertin, Kaitlyn B.
    Tahir, Muna J.
    Lewis, Hannah B.
    Wang, Julie
    Braverman, Julia
    Campbell, Timothy B.
    Dhanda, Devender
    Munshi, Nikhil C.
    BLOOD, 2020, 136
  • [43] OVERALL RESPONSE AND COMPLETE RESPONSE WITH ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) : A SYSTEMATIC REVIEW AND META-ANALYSIS
    Aggarwal, S.
    Bela, A.
    Topaloglu, O.
    VALUE IN HEALTH, 2020, 23 : S25 - S25
  • [44] Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study
    Lin, Yi
    Raje, Noopur S.
    Berdeja, Jesus G.
    Siegel, David S.
    Jagannath, Sundar
    Madduri, Deepu
    Liedtke, Michaela
    Rosenblatt, Jacalyn
    Maus, Marcela V.
    Massaro, Monica
    Petrocca, Fabio
    Caia, Andrea
    Yang, Zhihong
    Campbell, Timothy B.
    Hege, Kristen
    Munshi, Nikhil C.
    Kochenderfer, James N.
    BLOOD, 2020, 136
  • [45] Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)
    Mi, Jian-Qing
    Zhao, Wanhong
    Jing, Hongmei
    Fu, Weijun
    Hu, Jianda
    Chen, Lijuan
    Zhang, Yiwen
    Yao, Dan
    Chen, Diana
    Schecter, Jordan M.
    Yang, Fan
    Tian, Xiaochen
    Sun, Huabin
    Zhuang, Sen Hong
    Ren, Jimmy
    Fan, Xiaohu
    Jin, Jie
    Niu, Ting
    Chen, Sai-Juan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) : 1275 - +
  • [46] Chimeric Antigen Receptor-T (CAR-T) Cell Therapy Targeting BCMA in Patients with Prior Allogeneic Transplantation (allo-HCT) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Hammons, Lindsay
    Haider, Shabi
    Pasquini, Marcelo C.
    Chhabra, Saurabh
    Radhakrishnan, Sabarinath
    Zamora, Anthony E.
    Mohan, Meera
    Dong, Jing
    Janz, Siegfried
    D'Souza, Anita
    Hari, Parameswaran
    Dhakal, Binod
    BLOOD, 2022, 140 : 7215 - 7216
  • [47] Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
    Zhang, Lina
    Shen, Xuxing
    Yu, Wenjun
    Li, Jing
    Zhang, Jue
    Zhang, Run
    Li, Jianyong
    Chen, Lijuan
    ANNALS OF MEDICINE, 2021, 53 (01) : 1547 - 1559
  • [48] CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
    Mishra, Abhinava K.
    Gupta, Ashna
    Dagar, Gunjan
    Das, Dayasagar
    Chakraborty, Abhijit
    Haque, Shabirul
    Prasad, Chandra Prakash
    Singh, Archana
    Bhat, Ajaz A.
    Macha, Muzafar A.
    Benali, Moez
    Saini, Kamal S.
    Previs, Rebecca Ann
    Saini, Deepak
    Saha, Dwaipayan
    Dutta, Preyangsee
    Bhatnagar, Aseem Rai
    Darswal, Mrinalini
    Shankar, Abhishek
    Singh, Mayank
    VACCINES, 2023, 11 (11)
  • [49] B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study
    Cohen, Adam D.
    Garfall, Alfred L.
    Stadtmauer, Edward A.
    Lacey, Simon Francis
    Lancaster, Eric
    Vogl, Dan T.
    Dengel, Karen
    Ambrose, David E.
    Chen, Fang
    Plesa, Gabriela
    Kulikovskaya, Irina
    Gonzalez, Vanessa E.
    Gupta, Minnal
    Young, Regina M.
    Carey, Tenesia
    Ferthio, Regina
    Weiss, Brendan M.
    Richardson, Celeste
    Isaacs, Randi E.
    Melenhorst, J. Joseph
    Levine, Bruce L.
    June, Carl H.
    Milone, Michael C.
    BLOOD, 2016, 128 (22)
  • [50] A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Plesner, Torben
    Harrison, Simon J.
    Quach, Hang
    Lee, Cindy H.
    Bryant, Adam
    Vangsted, Annette Juul
    Estell, Jane
    Delforge, Michel
    Offner, Fritz
    Twomey, Patrick
    Choeurng, Voleak
    Li, Junyi
    Hendricks, Robert
    Sumiyoshi, Teiko
    Miller, Karen
    Choi, Eunpi
    Schjesvold, Fredrik H.
    BLOOD, 2021, 138
12345